Screener
Krystal Biotech, Inc. KRYS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
| Accumulated other comprehensive (loss) gain | (1,623) | 1,136 |
| Retained earnings | 80,095 | 24,163 |
| Total stockholders’ equity | 1,276,729 | 1,219,560 |
| Total liabilities and stockholders’ equity | $1,396,967 | $1,333,794 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s retained earnings?
- Krystal Biotech, Inc. (KRYS) reported retained earnings of $80.1M in Q1 2026.
- How has Krystal Biotech, Inc.'s retained earnings changed year-over-year?
- Krystal Biotech, Inc.'s retained earnings increased by 155.3% year-over-year, from -$144.94M to $80.1M.
- What is the long-term trend for Krystal Biotech, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s retained earnings has grown at a -19.4% compound annual growth rate (CAGR), from -$71.21M to $24.16M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Krystal Biotech, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude